Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2028

Conditions
Advanced Gastric Adenocarcinoma
Interventions
DRUG

Paclitaxel

"1. Patients will receive treatment on Day 1 and 8 starting with cycle 2.~2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~3. Drug - Paclitaxel - 80mg IV"

DRUG

Olaparib

"1. Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~2. Drug - 100 mg or 300mg"

DRUG

Pembrolizumab

"1. Patients will receive treatment every 21 days.~2. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~3. Drug - 200mg IV"

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center, Baltimore

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER